Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
Drug results: 2
| avutometinib | Avutometinib is a reversible inhibitor of RAF kinases and MEK1/2. Avutometinib inhibits RAF/MEK pathway signaling by binding to RAF kinases and MEK1/2, resulting in inhibition of phosphorylation of downstream extracellular signal-related kinase (ERK). Avutometinib in combination with defactinib enhanced inhibition of cell proliferation in vitro and anti-tumor activity in mouse tumor models including LGSOC. |
|
| defactinib | Defactinib is an inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2). FAK and PYK2 are non-receptor tyrosine kinases that regulate cellular signaling pathways involved in cell proliferation, survival, migration, and invasion. Defactinib inhibited FAK autophosphorylation in cancer cells in vitro and in mouse xenograft models. Avutometinib in combination with defactinib enhanced inhibition of cell proliferation in vitro and antitumor activity in mouse tumor models including LGSOC. |








Citing DrugCentral © 2026.
License